# A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy

> **NCT00271414** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 53 (actual)

## Conditions studied

- Chronic Pain

## Interventions

- **DRUG:** Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)

## Key facts

- **NCT ID:** NCT00271414
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** —
- **Final completion:** 2001-03
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00271414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00271414, "A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00271414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*